Exploring ways to slow down myopia progression using animal models
Application of an optical defocus model to explore mechanisms underlying myopia and control interventions
This study is looking at how to slow down myopia, or short-sightedness, by testing different medications in guinea pigs that have similar eyes to humans, to find better ways to help people with this condition.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Berkeley NIH-funded |
| Lab location | 1 site (Berkeley, United States) |
| Project ID | NIH-10952028 on NIH RePORTER |
What this research studies
This research investigates the mechanisms behind myopia, or short-sightedness, using a guinea pig model that mimics human eye structure. The study aims to test various pharmacological treatments, including combinations of levodopa and atropine, to see how they can inhibit the progression of myopia. Advanced imaging techniques and biometric measurements will be employed to assess the effectiveness of these treatments and understand their underlying mechanisms. By focusing on these innovative approaches, the research seeks to develop effective interventions for myopia control.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals, particularly children, who are at risk of developing or are currently experiencing myopia.
Not a fit: Patients with myopia who are not responsive to pharmacological treatments or those with advanced myopia complications may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that effectively slow the progression of myopia, potentially reducing the risk of serious eye complications.
How similar studies have performed: Previous research has shown promise in using pharmacological approaches to manage myopia, indicating that this study builds on established concepts while exploring novel combinations.
Where this research is happening
Berkeley, United States
- University of California Berkeley — Berkeley, United States (Active)
Researchers
- Principal investigator: Wildsoet, Christine Frances — University of California Berkeley
- Study coordinator: Wildsoet, Christine Frances
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.